Why Did a GLP-1 Receptor Agonist Fail This Parkinson’s Trial?

[ad_1]

(MedPage Today) — Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, Bydureon) did not slow Parkinson’s disease progression or improve symptoms, the phase III Exenatide-PD3 trial showed.
At 96 weeks, mean Movement Disorder Society…

[ad_2]

Source link : https://www.medpagetoday.com/neurology/parkinsonsdisease/114113

Author :

Publish date : 2025-02-06 20:35:02

Copyright for syndicated content belongs to the linked Source.